Integrated Approaches to Vaccine Safety Surveillance: Principles, Challenges, and Innovations
DOI:
https://doi.org/10.62896/ijpdd.2.8.03Keywords:
Vaccine safety surveillance; Adverse events following immunization (AEFI); Pharmacovigilance; Big data analytics; Artificial intelligence; Real-world evidence; Blockchain; Public trust; Global health; Immunization programsAbstract
Vaccine safety surveillance plays a pivotal role in ensuring public confidence and maintaining the integrity of immunization programs worldwide. With the rapid development and deployment of vaccines, particularly during global health emergencies, traditional surveillance methods alone are insufficient to address emerging challenges in detecting, evaluating, and managing adverse events following immunization (AEFI). This paper explores integrated approaches to vaccine safety surveillance, highlighting the principles that govern effective monitoring, the limitations of conventional systems, and the need for innovative strategies. It emphasizes the integration of epidemiological studies, pharmacovigilance systems, big data analytics, real-world evidence, artificial intelligence, and digital health tools to enhance early signal detection, causality assessment, and risk communication. Key challenges such as underreporting, data harmonization, ethical considerations, and public trust are critically analyzed. Furthermore, the paper discusses recent innovations including blockchain-enabled data security, machine learning algorithms for predictive modeling, and global collaborative platforms that strengthen vaccine safety monitoring. By adopting a multidimensional and technology-driven approach, stakeholders can build resilient surveillance systems that not only safeguard public health but also foster transparency, trust, and long-term sustainability of immunization programs.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sujata Publications

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.